椎旁注射阿米卡星联合利福布汀治疗耐药脊柱结核病的临床效果分析

Clinical Effect of Amikacin Combined with Rifabutin by Paravertebral Injection in Treatment of Drug-resistant Spinal Tuberculosis

目的观察并分析椎旁注射阿米卡星联合利福布汀治疗耐药脊柱结核病的临床效果。方法回顾性分析69例耐药脊柱结核患者的临床资料,并随机分为三组。A组(19例)应用利福布汀治疗,B组(24例)肌肉注射阿米卡星联合利福布汀治疗,C组(26例)应用椎旁注射阿米卡星联合利福布汀治疗。比较三组的临床治疗效果。结果 A组治愈率为42.11%,B组治愈率为50.00%,C组治愈率为88.46%;A组和B组相比差异不显著(P>0.05),C组显著高于A组和B组(P<0.05)。结论椎旁注射阿米卡星联合利福布汀治疗耐药脊柱结核病效果比单一及肌注用药效果更好,且安全有效,是临床上值得推广的用药方案。

Objective To observe and analyze the clinical effect of amikacin combined with rifabutin by paravertebral injection in treatmen of drug-resistant spinal tuberculosis. Methods Clinical data of 69 patients with drug-resistant spinal tuberculosis were retrospectively analyzed, all patients were randomly divided into three groups. Group A （19 cases） was treated with rifabutin by oral administration, group B （24 cases） was treated with amikacin combined with rifabutin by intramuscular injection, group C （26 cases） was treated with amikacin combined with rifabutin by paravertebral injection. The clinical effects of three groups were compared. Results The cure rate of group A, B, C were 42.11%, 50.00%and 88.46%respectively, no statistical difference was found between group A and group B （P〉0.05）, and the cure rate of group C was significantly higher than that of group A and B （P〈0.05）. Conclusions Amikacin combined with rifabutin by paravertebral injection has better effect than single medication and intramuscular medication in treatmen of drug-resistant spinal tuberculosis, which is safe and effective, and deserves promotion in clinic.